Paladin mounts hostile bid for Afexa

Paladin Labs is offering a modest premium in a hostile bid to take over Afexa Life Sciences, which makes the flu drug COLD-FX. In a deal that values the company at $56.7 million, Paladin has bid 55 cents a share for the 85% of the company it doesn't already own. Report

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.